Literature DB >> 31445109

Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer.

Suzanne Russo1, Christopher J Anker2, May Abdel-Wahab3, Nilofer Azad4, Prajnan Das5, Jadranka Dragovic6, Karyn A Goodman7, Joseph M Herman5, William Jones8, Timothy Kennedy9, Andre Konski10, Rachit Kumar11, Percy Lee12, Nell Maloney Patel13, Navesh Sharma14, William Small15, W Warren Suh16, Salma K Jabbour9.   

Abstract

The goal of treatment for early stage rectal cancer is to optimize oncologic outcome while minimizing effect of treatment on quality of life. The standard of care treatment for most early rectal cancers is radical surgery alone. Given the morbidity associated with radical surgery, local excision for early rectal cancers has been explored as an alternative approach associated with lower rates of morbidity. The American Radium Society Appropriate Use Criteria presented in this manuscript are evidence-based guidelines for the use of local excision in early stage rectal cancer that include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) used by a multidisciplinary expert panel to rate the appropriateness of imaging and treatment procedures. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. These guidelines are intended for the use of all practitioners and patients who desire information regarding the use of local excision in rectal cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31445109     DOI: 10.1016/j.ijrobp.2019.08.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Oncologic Nomogram for Stage I Rectal Cancer to Assist Patient Selection for Adjuvant (Chemo)Radiotherapy Following Local Excision.

Authors:  Shutao Zhao; Xin Chen; Dacheng Wen; Chao Zhang; Xudong Wang
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.